197 related articles for article (PubMed ID: 22752067)
1. Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis.
Boudou-Rouquette P; Ropert S; Mir O; Coriat R; Billemont B; Tod M; Cabanes L; Franck N; Blanchet B; Goldwasser F
Oncologist; 2012; 17(9):1204-12. PubMed ID: 22752067
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
Pécuchet N; Lebbe C; Mir O; Billemont B; Blanchet B; Franck N; Viguier M; Coriat R; Tod M; Avril MF; Goldwasser F
Br J Cancer; 2012 Jul; 107(3):455-61. PubMed ID: 22767146
[TBL] [Abstract][Full Text] [Related]
3. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma.
Mir O; Coriat R; Blanchet B; Durand JP; Boudou-Rouquette P; Michels J; Ropert S; Vidal M; Pol S; Chaussade S; Goldwasser F
PLoS One; 2012; 7(5):e37563. PubMed ID: 22666367
[TBL] [Abstract][Full Text] [Related]
4. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
Azad NS; Aragon-Ching JB; Dahut WL; Gutierrez M; Figg WD; Jain L; Steinberg SM; Turner ML; Kohn EC; Kong HH
Clin Cancer Res; 2009 Feb; 15(4):1411-6. PubMed ID: 19228742
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Okamoto I; Miyazaki M; Morinaga R; Kaneda H; Ueda S; Hasegawa Y; Satoh T; Kawada A; Fukuoka M; Fukino K; Tanigawa T; Nakagawa K
Invest New Drugs; 2010 Dec; 28(6):844-53. PubMed ID: 19760364
[TBL] [Abstract][Full Text] [Related]
6. Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.
Boudou-Rouquette P; Narjoz C; Golmard JL; Thomas-Schoemann A; Mir O; Taieb F; Durand JP; Coriat R; Dauphin A; Vidal M; Tod M; Loriot MA; Goldwasser F; Blanchet B
PLoS One; 2012; 7(8):e42875. PubMed ID: 22912756
[TBL] [Abstract][Full Text] [Related]
7. The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates.
Kim A; McCully C; Cruz R; Cole DE; Fox E; Balis FM; Widemann BC
Invest New Drugs; 2012 Apr; 30(2):524-8. PubMed ID: 21072558
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma.
Gomo C; Coriat R; Faivre L; Mir O; Ropert S; Billemont B; Dauphin A; Tod M; Goldwasser F; Blanchet B
Invest New Drugs; 2011 Dec; 29(6):1511-4. PubMed ID: 20706860
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
Furuse J; Ishii H; Nakachi K; Suzuki E; Shimizu S; Nakajima K
Cancer Sci; 2008 Jan; 99(1):159-65. PubMed ID: 17953709
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
Peer CJ; Sissung TM; Kim A; Jain L; Woo S; Gardner ER; Kirkland CT; Troutman SM; English BC; Richardson ED; Federspiel J; Venzon D; Dahut W; Kohn E; Kummar S; Yarchoan R; Giaccone G; Widemann B; Figg WD
Clin Cancer Res; 2012 Apr; 18(7):2099-107. PubMed ID: 22307138
[TBL] [Abstract][Full Text] [Related]
11. Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.
Quintela-Fandino M; Le Tourneau C; Duran I; Chen EX; Wang L; Tsao M; Bandarchi-Chamkhaleh B; Pham NA; Do T; MacLean M; Nayyar R; Tusche MW; Metser U; Wright JJ; Mak TW; Siu LL
Mol Cancer Ther; 2010 Mar; 9(3):751-60. PubMed ID: 20197396
[TBL] [Abstract][Full Text] [Related]
12. Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction.
Jain L; Gardner ER; Figg WD; Chernick MS; Kong HH
Pharmacotherapy; 2010 Jan; 30(1):52-6. PubMed ID: 20030473
[TBL] [Abstract][Full Text] [Related]
13. A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.
Tolcher AW; Appleman LJ; Shapiro GI; Mita AC; Cihon F; Mazzu A; Sundaresan PR
Cancer Chemother Pharmacol; 2011 Apr; 67(4):751-64. PubMed ID: 20521052
[TBL] [Abstract][Full Text] [Related]
14. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.
Maitland ML; Kasza KE; Karrison T; Moshier K; Sit L; Black HR; Undevia SD; Stadler WM; Elliott WJ; Ratain MJ
Clin Cancer Res; 2009 Oct; 15(19):6250-7. PubMed ID: 19773379
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib: a review of its use in advanced hepatocellular carcinoma.
Keating GM; Santoro A
Drugs; 2009; 69(2):223-40. PubMed ID: 19228077
[TBL] [Abstract][Full Text] [Related]
16. Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.
Vaishampayan UN; Burger AM; Sausville EA; Heilbrun LK; Li J; Horiba MN; Egorin MJ; Ivy P; Pacey S; Lorusso PM
Clin Cancer Res; 2010 Jul; 16(14):3795-804. PubMed ID: 20525756
[TBL] [Abstract][Full Text] [Related]
17. Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study.
Shinsako K; Mizuno T; Terada T; Watanabe J; Kamba T; Nakamura E; Ogawa O; Inui K
Int J Clin Oncol; 2010 Oct; 15(5):512-4. PubMed ID: 20340037
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
19. A phase II clinical trial of sorafenib in androgen-independent prostate cancer.
Dahut WL; Scripture C; Posadas E; Jain L; Gulley JL; Arlen PM; Wright JJ; Yu Y; Cao L; Steinberg SM; Aragon-Ching JB; Venitz J; Jones E; Chen CC; Figg WD
Clin Cancer Res; 2008 Jan; 14(1):209-14. PubMed ID: 18172272
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib and sunitinib.
Kim A; Balis FM; Widemann BC
Oncologist; 2009 Aug; 14(8):800-5. PubMed ID: 19648603
[No Abstract] [Full Text] [Related]
[Next] [New Search]